title: Hepatic cytochrome P450s, phase II enzymes and nuclear receptors are downregulated in a Th2 environment during Schistosoma mansoni infection.
abstract: Inflammation and infection downregulate the activity and expression of cytochrome P450s (P450s) and other drug metabolizing enzymes (DMEs) involved in hepatic drug clearance. Schistosoma mansoni infection was reported to cause a downregulation of hepatic P450-dependent activities in mouse liver, but little is known about the specific enzymes affected or whether phase II DMEs are also affected. Here we describe the effect of murine schistosomiasis on the expression of hepatic P450s, NADPH-cytochrome P450 reductase (Cpr), phase II drug metabolizing enzymes, and nuclear receptors at 30 and 45 days postinfection (dpi). Although the hepatic expression of some of these genes was altered at 30 dpi, we observed substantial changes in the expression of the majority of P450 mRNAs and proteins measured, Cpr protein, as well as many of the UDP-glucuronosyltransferases and sulfotransferases at 45 dpi. S. mansoni infection also altered nuclear receptor expression, inducing mRNA levels at 30 dpi and depressing levels at 45 dpi. S. mansoni evoked a T helper 2 (Th2) inflammatory response at 45 dpi, as indicated by the induction of hepatic Th2 cytokine mRNAs [interleukins 4, 5, and 13], whereas the hepatic proinflammatory response was relatively weak. Thus, chronic schistosomiasis markedly and selectively alters the expression of multiple DMEs, which may be associated with Th2 cytokine release. This would represent a novel mechanism of DME regulation in disease states. These findings have important implications for drug testing in infected mice, whereas the relevance to humans with schistosomiasis needs to be determined.
authors.affiliation: Departments of Pharmacology (S.M.M., B.A.N., M.D.M., C.-M.L., E.T.M.) and Biochemistry (N.S.P., R.D.C.), Emory University School of Medicine, Atlanta, Georgia.
authors.forename: Sylvie M
authors.initials: SM
authors.lastname: Mimche
authors.forename: Beatrice A
authors.initials: BA
authors.lastname: Nyagode
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Merrell
authors.forename: Choon-Myung
authors.initials: CM
authors.lastname: Lee
authors.forename: Nina S
authors.initials: NS
authors.lastname: Prasanphanich
authors.forename: Richard D
authors.initials: RD
authors.lastname: Cummings
authors.forename: Edward T
authors.initials: ET
authors.lastname: Morgan
mesh_terms: D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D015536:Down-Regulation / Q000235:genetics*; D005260:Female; D014453:Glucuronosyltransferase / Q000235:genetics / Q000378:metabolism; D007249:Inflammation / Q000235:genetics / Q000378:metabolism; D008099:Liver / Q000201:enzymology* / Q000378:metabolism*; D050217:Metabolic Detoxication, Phase II / Q000235:genetics*; D051379:Mice; D009251:NADPH-Ferrihemoprotein Reductase / Q000235:genetics / Q000378:metabolism; D010105:Oxygenases / Q000235:genetics / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism*; D012552:Schistosomiasis / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D012555:Schistosomiasis mansoni / Q000201:enzymology* / Q000235:genetics / Q000378:metabolism; D015238:Sulfotransferases / Q000235:genetics / Q000378:metabolism; D018418:Th2 Cells / Q000378:metabolism*
chemical_list: D016207:Cytokines; D018160:Receptors, Cytoplasmic and Nuclear; D003577:Cytochrome P-450 Enzyme System; D010105:Oxygenases; C020066:dimethylaniline monooxygenase (N-oxide forming); D009251:NADPH-Ferrihemoprotein Reductase; D014453:Glucuronosyltransferase; D015238:Sulfotransferases